MA51146B1 - Bicyclic substituted heterocyclic compounds used as prmt5 inhibitors - Google Patents
Bicyclic substituted heterocyclic compounds used as prmt5 inhibitorsInfo
- Publication number
- MA51146B1 MA51146B1 MA51146A MA51146A MA51146B1 MA 51146 B1 MA51146 B1 MA 51146B1 MA 51146 A MA51146 A MA 51146A MA 51146 A MA51146 A MA 51146A MA 51146 B1 MA51146 B1 MA 51146B1
- Authority
- MA
- Morocco
- Prior art keywords
- heterocyclic compounds
- substituted heterocyclic
- compounds used
- prmt5 inhibitors
- bicyclic substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des composés hétérocycliques bicycliques substitués de formule (i), des sels pharmaceutiquement acceptables de ceux-ci et des compositions pharmaceutiques pour le traitement de maladies, de troubles ou d'états pathologiques associés à la surexpression de l'enzyme prmt5. L'invention concerne également des méthodes de traitement de maladies, de troubles ou d'états pathologiques associés à la surexpression de l'enzyme prmt5.Disclosed herein are substituted bicyclic heterocyclic compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions for the treatment of diseases, disorders, or disease states associated with overexpression of the enzyme prmt5. Also provided are methods of treating diseases, disorders, or disease states associated with overexpression of the enzyme prmt5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721044886 | 2017-12-13 | ||
| PCT/IB2018/060015 WO2019116302A1 (en) | 2017-12-13 | 2018-12-13 | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51146A MA51146A (en) | 2021-03-24 |
| MA51146B1 true MA51146B1 (en) | 2022-10-31 |
Family
ID=83995765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51146A MA51146B1 (en) | 2017-12-13 | 2018-12-13 | Bicyclic substituted heterocyclic compounds used as prmt5 inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA51146B1 (en) |
-
2018
- 2018-12-13 MA MA51146A patent/MA51146B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA51146A (en) | 2021-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43169B1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
| MA47079B1 (en) | Amino-triazolopyidin compounds and their use to treat cancer | |
| EP4356973A3 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MA40123A1 (en) | Pyrimidines used as factor xia inhibitors | |
| MA43979B1 (en) | 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders | |
| MA44674B1 (en) | Bromodomain inhibitors | |
| MA39554A3 (en) | Spirocycloheptanes used as rock inhibitors | |
| EA201691428A1 (en) | BICYCLIC HETEROCYCLIC DERIVATIVES AS IRAK4 INHIBITORS | |
| MA41179A (en) | PARG INHIBITOR COMPOUNDS | |
| EA200900152A1 (en) | PYRROLOTRIAZINKINASE INHIBITORS | |
| MA54133B1 (en) | Aminopyrazine diol compounds used as pi3k-y inhibitors | |
| MA46229B1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MA49956B1 (en) | Pyrimidine compounds used as jak kinase inhibitors | |
| MA40955A (en) | 2-AMINO-6- (DIFLUOROMETHYL) -5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS | |
| EA202192900A1 (en) | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAYS | |
| MA50013B1 (en) | BENZOAZEPINE ANALOGS AS BRUTON'S TYROSINE KINASE INHIBITORS | |
| MA43052B1 (en) | Human Plasma Kallikrein Inhibitors | |
| MA41633B1 (en) | Amide Compounds as 5-HT4 Receptor Agonists | |
| MX2021010122A (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders. | |
| MX2022003873A (en) | Substituted 1, 6-naphthyridine inhibitors of cdk5. | |
| MA53372B1 (en) | Pyridopyrimidinenes as histamine h4 receptor inhibitors | |
| MA51146B1 (en) | Bicyclic substituted heterocyclic compounds used as prmt5 inhibitors | |
| MA44383B1 (en) | A derivative of 4- (3-pyrazolylamino) -benzimidazole as a jak1 inhibitor for the treatment of cancer |